Evommune (EVMN) Corporate presentation summary

Chronic inflammation and market opportunity

• Chronic inflammation is a major global health crisis, causing 3 out of 5 deaths and costing $90B annually.

• Over 234M people are diagnosed with immunological diseases, with >50% of I&I therapies failing patients.

• Advanced therapies for these conditions generate over $100B in sales, with significant unmet needs.

Portfolio and pipeline overview

• The portfolio includes EVO301 (IL-18BP), EVO756 (MRGPRX2 antagonist), and EVO646 (TLR7/8 antagonist), each targeting distinct mechanisms in chronic inflammation.

• EVO301 targets atopic dermatitis and other IL-18-driven diseases; EVO756 addresses migraine prevention; EVO646 is aimed at autoimmune diseases.

• Multiple programs are advancing through preclinical and clinical stages, with Phase 2b and Phase 1 trials planned for 2027.

EVO301: Atopic dermatitis and IL-18-driven diseases

• EVO301 is a long-acting, injectable IL-18BP fusion protein designed to neutralize IL-18 signaling, addressing both innate and adaptive inflammation.

• Phase 2a trial in moderate-to-severe atopic dermatitis showed 34% placebo-adjusted EASI improvement at week 8, with no serious adverse events.

• Efficacy was comparable to dose-optimized marketed biologics, with no conjunctivitis reported.

• The AD market is projected to reach $60B, with EVO301 positioned for foundational therapy status.

• Phase 2b dose-ranging trial in AD is planned for mid-2027.